Impact of relative dose intensity of first-line platinum-based chemotherapy in patients with thymic epithelial tumors: a retrospective study

Therapeutic Advances in Medical Oncology 2026 Open access

Read full text
Authors: Erica Pietroluongo, Pietro De Placido, Roberto Buonaiuto, Aldo Caltavituro, Giuseppe Neola, Margaret Ottaviano, Marianna Tortora, Grazia Arpino, Giovannella Palmieri, Carmine De Angelis, Marina Chiara Garassino, Roberto Bianco
+2 more Alberto Servetto, Mario Giuliano
DOI: 10.1177/17588359251411122
Cited by: 0
References: 14

Abstract

Background: Platinum-based chemotherapy is the first-line treatment choice for advanced thymic epithelial tumors (TETs), with the expected objective response rate (ORR) ≈of 50% in thymoma and ≈20% in thymic carcinoma. Objective: To evaluate the impact of relative dose intensity (RDI) on first-line treatment outcomes in TET patients. Design: Retrospective cohort referred between 2016 and 2022 at the University of Naples Federico II, Italy. Methods: Advanced TETs treated with first-line platinum chemotherapy; RDI calculated as delivered/planned dose intensity and categorized as low (

Fields of Study & Subjects

Myasthenia Gravis and Thymoma Testicular diseases and treatments Cardiac tumors and thrombi

Publication details

Journal / source
Therapeutic Advances in Medical Oncology
Volume
18
Pages
17588359251411122–17588359251411122
Publication date
1 February 2026
Language
EN